IlluminaXTER:ILU +0.60%76 FCF Margin % is 23.01% as of Mar. 2026, which is 11% above its 10-year median of 20.82. GuruFocus rates XTER:ILU with a GF Score™ of 76/100 and a GF Value™ of €91.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Illumina ranks better than 91.67% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Illumina's Free Cash Flow for the
three
months ended in Mar. 2026 was €217 Mil. Illumina's Revenue for the
three
months ended in Mar. 2026 was €944 Mil. Therefore, Illumina's FCF Margin % for the quarter that ended in Mar. 2026 was 23.01%.
The historical rank and industry rank for Illumina's FCF Margin % or its related term are showing as below:
XTER:ILU'
s FCF Margin % Range Over the Past 10 Years
Min: 2.31 Med: 20.82 Max: 27.51
Current: 22.16
During the past 13 years, the highest FCF Margin % of Illumina was 27.51%. The lowest was 2.31%. And the median was 20.82%.
XTER:ILU's FCF Margin % is ranked better than 91.67% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs XTER:ILU: 22.16
Illumina FCF Margin % Related Terms
Illumina FCF Margin % Historical Data
* Premium members only.
The historical data trend for Illumina's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Illumina's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Illumina's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XTER:ILU) has a FCF Margin % of 23.01% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Illumina and its competitors. This is 11% above median its historical median of 20.82. Over the past decade, Illumina's FCF Margin % has ranged from 2.31 to 27.51. According to the industry distribution chart, Illumina ranks #17 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 8.3%.
Is Illumina's FCF Margin % too high?
Illumina's current FCF Margin % of 23.01% is 11% above median its 10-year median of 20.82. Over the past 10 years, this metric has ranged from a low of 2.31 to a high of 27.51. Based on the distribution chart, Illumina ranks #17 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Illumina has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Illumina's FCF Margin % compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #17 out of 204 companies for FCF Margin %. This places Illumina in the top 8% of its industry — outperforming the majority of peers. Historically, Illumina's own FCF Margin % has ranged from 2.31 to 27.51 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Illumina and its competitors. Illumina's current FCF Margin % is 23.01%, which is 11% above median its own 10-year median of 20.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Based on GuruFocus' analysis, Illumina (XTER:ILU) is currently considered Significantly Overvalued. The stock's GF Value™ is €91.68, compared to a current price of €124.28 — trading 35.6% above its estimated fair value. The current FCF Margin % is 23.01%, which is 11% above median its 10-year median of 20.82. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Illumina (XTER:ILU), the current FCF Margin % is 23.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XTER:ILU) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of €124.28 is trading 35.6% above its estimated GF Value™ of €91.68.
GuruFocus considers Illumina to be Significantly Overvalued.
Key valuation signals for XTER:ILU:
FCF Margin %: 23.01% (11% above median its 10-year median of 20.82)
GF Value™: €91.68 vs. price of €124.28 (35.6% above fair value)
No single metric tells the full story. See the XTER:ILU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XTER:ILU
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:ILU has been successfully added to your 
